JP Morgan Initiates Coverage On Definium Therapeutics with Overweight Rating, Announces Price Target of $84
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsInitiationPrice Target
JP Morgan initiates coverage on Definium Therapeutics (NASDAQ:DFTX) with a Overweight rating and announces Price Target of $84.
JP Morgan initiates coverage on Definium Therapeutics (NASDAQ:DFTX) with a Overweight rating and announces Price Target of $84.